Eosinophilic Gastroenteritis Market Summary

Eosinophilic Gastroenteritis Insights and Trends

• The dynamics of the eosinophilic gastroenteritis market is expected to evolve significantly during the forecast period due to increasing disease awareness, improved diagnostic recognition, advances in eosinophil-targeted therapies, and the anticipated launch of novel biologics and precision immunomodulatory agents.
• Further, the patient burden of eosinophilic gastroenteritis may remain underestimated due to delayed diagnosis, nonspecific symptom presentation, and the lack of universally standardized diagnostic criteria, indicating potential opportunity for further expansion of the diagnosed patient population during the forecast period.
• There are currently no FDA-approved therapies indicated specifically for eosinophilic gastroenteritis, and treatment remains largely dependent on off-label approaches including corticosteroids, proton pump inhibitors, dietary interventions, and leukotriene inhibitors, immunosuppressive agents, and symptomatic management strategies.
• Glucocorticoids are the mainstay treatment for eosinophilic gastroenteritis. The dose of steroids should be tapered quickly over two weeks. The goal of the tapering dose of steroids is to treat severe symptoms, not tissue eosinophilia because fibrosis is comparatively less common than eosinophilic esophagitis.
• Empiric elimination diets and food restriction strategies are commonly used, particularly in pediatric patients and those with malabsorption, where dietary modification is often considered first-line before corticosteroid therapy; however, long-term efficacy remains inadequately established, and careful monitoring is required due to the risk of relapse or steroid resistance. 
• Immunosuppressive drugs like azathioprine may be considered in refractory or steroid-dependent cases, while surgical intervention may be required in severe patients presenting with intestinal obstruction. 
• Mast cell membrane stabilizers, such as sodium cromoglycate, and antihistaminic drugs, like ketotifen, have also been used in the treatment of eosinophilic gastroenteritis alone or in combination with steroids, although with inconsistent results.
• Conventional treatment approaches continue to face substantial limitations, as long-term corticosteroid exposure is associated with safety concerns and relapses are frequently observed after treatment discontinuation, creating a persistent unmet need for durable and disease-modifying therapies.
• Growing understanding of type 2 inflammatory pathways and eosinophilic biology is increasingly reshaping therapeutic development, supporting a transition toward targeted biologics that address underlying disease mechanisms rather than symptom control alone.
• Biologic therapies targeting IL-5, and IL-4/IL-13 are emerging as one of the most promising next-generation therapeutic classes due to their potential to reduce eosinophilic inflammation and improve long-term disease control.
• Emerging pipeline programs are increasingly focusing on precision medicine approaches, aiming to stratify patients according to inflammatory biomarkers and disease characteristics to optimize treatment selection and clinical outcomes.
• The treatment paradigm is gradually shifting from temporary symptom management toward long-term disease control, reduction of eosinophilic inflammation, prevention of recurrence, and improvement of patient-reported outcomes, which is expected to reshape future therapeutic development in eosinophilic gastroenteritis.

Eosinophilic Gastroenteritis and Forecast in the 7MM

• 2025 Eosinophilic Gastroenteritis Market Size: ~USD XX million

• 2036 Eosinophilic Gastroenteritis Market Size: ~USD XX million
• Eosinophilic Gastroenteritis Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Eosinophilic Gastroenteritis – Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the Eosinophilic Gastroenteritis , historical and forecasted epidemiology, as well as Eosinophilic Gastroenteritis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Eosinophilic Gastroenteritis market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates eosinophilic gastroenteritis patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in Eosinophilic Gastroenteritis and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Eosinophilic Gastroenteritis Market

Eosinophilic Gastroenteritis Patient Pool and Rising Disease Burden

Increasing recognition of eosinophilic gastrointestinal diseases (EGIDs), improved endoscopic and histopathological diagnosis, growing physician awareness, and broader identification of previously underdiagnosed patients are expected to drive growth in the eosinophilic gastroenteritis market, particularly in the United States where advanced diagnostic infrastructure and specialized gastroenterology referral centers support higher disease detection and management.

Eosinophilic Gastroenteritis Emerging Therapies

Emerging biologics targeting IL-5, IL-4/IL-13, Siglec-8, and other eosinophil-associated pathways are poised to transform eosinophilic gastroenteritis management by improving symptom control, reducing eosinophilic inflammation, enabling durable remission, and minimizing long-term corticosteroid dependence.

Eosinophilic Gastroenteritis Clinical Trials and Competitive Landscape

The EGE pipeline is advancing rapidly, driven by biologics targeting IL-4/IL-13, and IL-5 pathways. Leading companies, including Sanofi, Regeneron Pharmaceuticals, and others, are shaping a competitive landscape increasingly focused on precision therapies that aim to improve disease control and reduce corticosteroid dependence.

Eosinophilic Gastroenteritis Understanding and Treatment Algorithm

Eosinophilic Gastroenteritis Overview and Diagnosis

Eosinophilic gastroenteritis is a rare, chronic inflammatory gastrointestinal disorder characterized by eosinophilic infiltration of the gastrointestinal tract in the absence of secondary causes of eosinophilia such as parasitic infections, malignancies, or systemic inflammatory disorders. The disease can affect multiple layers of the gastrointestinal wall, including the mucosal, muscular, and serosal layers, leading to heterogeneous clinical manifestations depending on the site and depth of involvement. It is considered part of the broader spectrum of eosinophilic gastrointestinal diseases (EGIDs) and is frequently associated with allergic conditions including asthma, food allergies, eczema, and other atopic disorders. Clinical manifestations vary widely and commonly include abdominal pain, nausea, vomiting, diarrhea, bloating, weight loss, anemia, gastrointestinal bleeding, and nutritional deficiencies, often resulting in substantial quality-of-life impairment.

Eosinophilic Gastroenteritis Diagnosis

Diagnosis of eosinophilic gastroenteritis remains challenging due to its nonspecific presentation and clinical overlap with multiple gastrointestinal disorders. Diagnosis generally begins with comprehensive clinical assessment, symptom evaluation, laboratory investigations, and exclusion of secondary causes of eosinophilia. Endoscopy with multiple gastrointestinal biopsies remains the cornerstone of diagnosis, allowing histopathological identification of abnormal eosinophilic infiltration within gastrointestinal tissues. Additional diagnostic tools including complete blood count with eosinophil evaluation, serum immunoglobulin E (IgE) assessment, allergy testing, imaging studies, and endoscopic evaluation may support disease characterization. Early and accurate diagnosis is critical to minimize delays in treatment, reduce complications, and support selection of appropriate targeted therapeutic strategies.

Further details are provided in the report.

Eosinophilic Gastroenteritis Treatment

The treatement of eosinophilic gastroenteritis is highly individualized, guided by disease severity, symptom burden, extent of eosinophilic infiltration, and associated allergic conditions, with current strategies focused on reducing inflammation, achieving symptom control and remission, and preventing relapse. Treatment commonly includes dietary modification, corticosteroids, proton pump inhibitors, leukotriene inhibitors, immunosuppressants, and supportive nutritional care, with corticosteroids such as prednisone and budesonide remaining the mainstay due to their rapid anti-inflammatory effect, despite limitations related to long-term safety and high relapse rates. The therapeutic landscape is gradually evolving with growing interest in targeted biologics for patients with severe, recurrent, or steroid-dependent disease, including agents directed against IL-5, IL-4/IL-13, Siglec-8, and other eosinophil-associated pathways, reflecting a broader shift toward precision-based, disease-modifying approaches aimed at improving durable disease control and long-term outcomes.

Further details related to country-based variations are provided in the report.

Eosinophilic Gastroenteritis Unmet Needs

The section “unmet needs of Eosinophilic Gastroenteritis” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress. 

• Lack of highly effective and durable therapies for sustained remission and relapse prevention
• Absence of approved disease-specific therapies
• Long-term dependence on corticosteroids, limited by safety concerns and frequent relapse 
• Limited treatment options remain for severe and refractory disease
• Delayed and challenging diagnosis, and others…

Comprehensive unmet needs insights in Eosinophilic Gastroenteritis and their strategic implications are provided in the full report.

Eosinophilic Gastroenteritis Epidemiology

Key Findings from Eosinophilic Gastroenteritis Epidemiological Analysis and Forecast

• The prevalence of eosinophilic gastroenteritis is increasing globally, primarily driven by improved recognition of EGIDs, increasing physician awareness, advancement endoscopic and histopathological diagnostic approaches, and broader identification of previously underdiagnosed patients, and increasing prevalence of allergic and atopic disorders.
• The United States accounts for a highest number of diagnosed eosinophilic gastroenteritis cases across the 7MM due to higher disease awareness, access to specialist gastroenterology care, and increasing use of endoscopy with biopsy-based diagnostic evaluation.
• Eosinophilic gastroenteritis frequently affects younger and middle-aged adults, although disease can occur across all age groups. 
• Eosinophilic gastroenteritis shows a male predominance, with men representing a greater proportion of diagnosed cases as compared to females. 
• The mucosal subtype accounts for the majority (50–100%) of diagnosed eosinophilic gastroenteritis cases, followed by muscularis (10%–30%) and subserosal (10%–15%) subtypes.

Eosinophilic Gastroenteritis Drug Chapters & Competitive Analysis

The Eosinophilic Gastroenteritis drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase II clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Eosinophilic Gastroenteritis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Eosinophilic Gastroenteritis therapeutics market.

Eosinophilic Gastroenteritis Pipeline Analysis

Dupilumab (DUPIXENT): Regeneron Pharmaceuticals/Sanofi 

Dupilumab is a fully human monoclonal antibody that blocks IL-4 and IL-13 signaling, two key drivers of type 2 inflammation implicated in eosinophilic gastroenteritis. By targeting these pathways, Dupixent aims to reduce eosinophilic inflammation, improve gastrointestinal symptoms, and achieve sustained disease control without broadly suppressing the immune system. 

The drug successfully completed a Phase II clinical trial in eosinophilic gastroenteritis in 2024 and is currently being evaluated in an ongoing Phase II study in adult and adolescent patients with eosinophilic gastritis, with or without eosinophilic duodenitis.

Note: A detailed emerging therapies assessment will be provided in the final report

Eosinophilic Gastroenteritis Key Players, Market Leaders and Emerging Companies

• Sanofi
• Regeneron Pharmaceuticals, and others…

Eosinophilic Gastroenteritis Key Players Drug Updates

• In May 2025, Regeneron Pharmaceuticals presented Phase II results from the DEGAS trial at the Digestive Disease Week (DDW) 2025, demonstrating that dupilumab improved histologic and endoscopic features in patients with eosinophilic gastritis in a multicenter, randomized, double-blind, placebo-controlled study.
• In February 2025, cendakimab, Bristol Myers Squibb’s IL-13-targeting antibody, failed to meet expectations despite earlier Phase III success in eosinophilic esophagitis. Subsequently, Bristol Myers Squibb discontinued the program and quietly removed cendakimab from its pipeline.
• In January 2024, Allakos discontinued the development of lirentelimab (AK-002), its anti-Siglec-8 antibody, for eosinophilic gastrointestinal diseases, including eosinophilic gastroenteritis, following broader clinical and strategic setbacks,
• In February 2024, AstraZeneca discontinued the Phase III HUDSON GI trial evaluating benralizumab (FASENRA) in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis.

Drug Class Insights

Eosinophilic Gastroenteritis Market Outlook

Eosinophilic Gastroenteritis remains an area of high unmet need, with no therapies currently approved specifically for the disease. Current treatment relies on off-label approaches, including corticosteroids (prednisone, budesonide), dietary modifications, proton pump inhibitors, and immunosuppressive agents, which provide symptomatic relief but are often associated with relapse and long-term treatment burden.

The eosinophilic gastroenteritis pipeline has undergone significant shifts in recent years. While dupilumab (DUPIXENT) has emerged as a leading investigational therapy targeting IL-4/IL-13-mediated type 2 inflammation, several earlier contenders have faced setbacks. Lirentelimab (Allakos) was discontinued after histologic improvements did not consistently translate into meaningful symptom benefits. Cendakimab (Bristol Myers Squibb) was terminated due to limited enrollment and evolving insights into disease pathology. Similarly, benralizumab (AstraZeneca) was discontinued in EGE despite demonstrating eosinophil depletion, as its clinical benefit did not sufficiently support further development.  Overall, despite the discontinuation of lirentelimab, benralizumab, and cendakimab, the continued advancement of dupilumab underscores the potential of targeted biologics to reshape EGE treatment through durable disease control and reduced corticosteroid reliance. 

Further details will be provided in the report….

Drug Class/Insights into Leading Emerging and Marketed Therapies in Eosinophilic Gastroenteritis (2022–2036 Forecast)

The Eosinophilic Gastroenteritis market (2022–2036) is primarily driven by the development of targeted biologic therapies aimed at addressing the underlying type 2 inflammatory pathways and eosinophilic disease mechanisms rather than relying solely on symptomatic management and supportive care.

IL-4 and IL-13 Inhibitors: The EGE treatment landscape is increasingly centered around therapies targeting the IL-4 and IL-13 pathways, which play a central role in type 2 inflammation and eosinophilic disease pathogenesis. Among the leading candidates, dupilumab, developed by Sanofi and Regeneron, is a fully human monoclonal antibody designed to inhibit IL-4 and IL-13 signaling. By blocking these key inflammatory pathways, dupilumab aims to reduce eosinophilic infiltration, improve gastrointestinal symptoms, and provide sustained disease control.

Eosinophilic Gastroenteritis innovation is currently driven by IL-4 and IL-13 inhibition focused on addressing the underlying inflammatory mechanisms of disease, representing a significant shift toward disease-modifying treatment strategies in this rare gastrointestinal disorder.

Further details are provided in the final report….

Eosinophilic Gastroenteritis Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the Eosinophilic Gastroenteritis market's uptake by drugs, patient uptake by therapy, and sales of each drug.

The uptake of therapies in eosinophilic gastroenteritis is expected to increasingly shift from conventional off-label treatments toward targeted biologic and immunomodulatory therapies over the forecast period. Existing approaches, including corticosteroids, budesonide, dietary elimination strategies, proton pump inhibitors, and immunosuppressive agents, are likely to maintain baseline use due to established clinical experience and rapid symptom relief; however, their long-term uptake may gradually decline due to safety concerns, steroid dependence, relapse after discontinuation, adherence challenges, and variable durability of response. Emerging biologics such as dupilumab (DUPIXENT) are anticipated to witness growing uptake owing to their potential to reduce corticosteroid burden and provide improved symptomatic, histologic, and long-term disease control.

Further detailed analysis of emerging therapies' drug uptake in the report…

Market Access and Reimbursement of Eosinophilic Gastroenteritis

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Further details are provided in the final report….

Eosinophilic Gastroenteritis Therapies Price Scenario & Trends 

Pricing and analogue assessment of Eosinophilic Gastroenteritis therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report….

Industry Experts and Physician Views for Eosinophilic Gastroenteritis

To keep up with Eosinophilic Gastroenteritis market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the eosinophilic gastroenteritis emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Eosinophilic Gastroenteritis, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the Cincinnati Children's Center for Eosinophilic Disorders, University of North Carolina Center for Esophageal Diseases and Swallowing, etc. were contacted. Their opinion helps understand and validate current and emerging eosinophilic gastroenteritis therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in eosinophilic gastroenteritis.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. In the SWOT analysis of Eosinophilic Gastroenteritis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of eosinophilic gastroenteritis, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Eosinophilic Gastroenteritis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Eosinophilic Gastroenteritis market. 

Report Insights

• Eosinophilic Gastroenteritis Patient Population Forecast
• Eosinophilic Gastroenteritis Therapeutics Market Size 
• Eosinophilic Gastroenteritis Pipeline Analysis
• Eosinophilic Gastroenteritis Market Size and Trends
• Eosinophilic Gastroenteritis Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report 
• 11-year forecast 
• Eosinophilic Gastroenteritis Market Outlook (North America, Europe, Asia-Pacific) 
• Patient Burden Trends (by geography)
• Eosinophilic Gastroenteritis Treatment Addressable Market (TAM)
• Eosinophilic Gastroenteritis Competitive Landscape
• Eosinophilic Gastroenteritis Major Companies Insights
• Eosinophilic Gastroenteritis Price Trends and Analogue Assessment
• Eosinophilic Gastroenteritis Therapies Drug Adoption/Uptake
• Eosinophilic Gastroenteritis Therapies Peak Patient Share analysis

Report Assessment

• Eosinophilic Gastroenteritis Current Treatment Practices
• Eosinophilic Gastroenteritis Unmet Needs
• Eosinophilic Gastroenteritis Clinical Development Analysis
• Eosinophilic Gastroenteritis Emerging Drugs Product Profiles
• Eosinophilic Gastroenteritis Market Attractiveness
• Eosinophilic Gastroenteritis Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

Market Insights

• What was the eosinophilic gastroenteritis market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of eosinophilic gastroenteritis?
• What are the disease risks, burdens, and unmet needs of eosinophilic gastroenteritis? What will be the growth opportunities across the 7MM concerning the patient population with eosinophilic gastroenteritis?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of eosinophilic gastroenteritis? What are the current guidelines for treating Eosinophilic Gastroenteritis in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the eosinophilic gastroenteritis market.
• Bottom-up forecasting builds from the affected population to product forecasts, delivering a robust, data-driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)-enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data-driven decisions.